Several analysts have recently updated their ratings and price targets for Thermo Fisher Scientific (NYSE: TMO):

  • 9/28/2017 – Thermo Fisher Scientific had its “hold” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $195.00 price target on the stock.
  • 9/26/2017 – Thermo Fisher Scientific is now covered by analysts at Goldman Sachs Group, Inc. (The). They set a “buy” rating and a $225.00 price target on the stock.
  • 9/25/2017 – Thermo Fisher Scientific had its “overweight” rating reaffirmed by analysts at Barclays PLC. They now have a $215.00 price target on the stock, up previously from $200.00.
  • 9/21/2017 – Thermo Fisher Scientific was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $212.00 price target on the stock. According to Zacks, “Over the last three months, Thermo Fisher is trading above the broader industry. Thermo Fisher ended the second quarter on a promising note. We are particularly upbeat about the company gaining entry into the CDMO market through the recent acquistion of Patheon for $7.2 billion. We are also encouraged by the company’s series of product launches along with major progress in precision medicine initiatives. Thermo Fisher’s acquisition of FEI Company has already started to boost its analytical instruments portfolio. The company also opened Center of Excellence for electron microscopy in Saudi Arabia. The raised 2017 guidance is all the more encouraging indicating the fact that this overall bullish trend will continue through the year.”
  • 9/18/2017 – Thermo Fisher Scientific was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Over the last three months, Thermo Fisher is trading above the broader industry. Thermo Fisher ended the second quarter on a promising note. We are particularly upbeat about the company gaining entry into the CDMO market through the recent acquistion of Patheon for $7.2 billion. We are also encouraged by the company’s series of product launches along with major progress in precision medicine initiatives. Thermo Fisher’s acquisition of FEI Company has already started to boost its analytical instruments portfolio. The company also opened Center of Excellence for electron microscopy in Saudi Arabia. The raised 2017 guidance is all the more encouraging indicating the fact that this overall bullish trend will continue through the year.”
  • 9/14/2017 – Thermo Fisher Scientific was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $214.00 price target on the stock. According to Zacks, “Over the last three months, Thermo Fisher is trading above the broader industry. Thermo Fisher ended the second quarter on a promising note. We are particularly upbeat about the company gaining entry into the CDMO market through the recent acquistion of Patheon for $7.2 billion. We are also encouraged by the company’s series of product launches along with major progress in precision medicine initiatives. Thermo Fisher’s acquisition of FEI Company has already started to boost its analytical instruments portfolio. The company also opened Center of Excellence for electron microscopy in Saudi Arabia. The raised 2017 guidance is all the more encouraging indicating the fact that this overall bullish trend will continue through the year.”
  • 9/12/2017 – Thermo Fisher Scientific was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Over the last three months, Thermo Fisher is trading above the broader industry. Thermo Fisher ended the second quarter on a promising note. We are particularly upbeat about the company gaining entry into the CDMO market through the recent acquistion of Patheon for $7.2 billion. We are also encouraged by the company’s series of product launches along with major progress in precision medicine initiatives. Thermo Fisher’s acquisition of FEI Company has already started to boost its analytical instruments portfolio. The company also opened Center of Excellence for electron microscopy in Saudi Arabia. The raised 2017 guidance is all the more encouraging indicating the fact that this overall bullish trend will continue through the year.”
  • 9/10/2017 – Thermo Fisher Scientific had its “outperform” rating reaffirmed by analysts at Cowen and Company. They now have a $220.00 price target on the stock, up previously from $200.00.
  • 9/7/2017 – Thermo Fisher Scientific was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $208.00 price target on the stock. According to Zacks, “Over the last three months, Thermo Fisher is trading above the broader industry. Thermo Fisher ended the second quarter on a promising note. We are particularly upbeat about the company gaining entry into the CDMO market through the recent acquistion of Patheon for $7.2 billion. We are also encouraged by the company’s series of product launches along with major progress in precision medicine initiatives. Thermo Fisher’s acquisition of FEI Company has already started to boost its analytical instruments portfolio. The company also opened Center of Excellence for electron microscopy in Saudi Arabia. The raised 2017 guidance is all the more encouraging indicating the fact that this overall bullish trend will continue through the year.”
  • 9/6/2017 – Thermo Fisher Scientific had its “overweight” rating reaffirmed by analysts at Morgan Stanley. They now have a $220.00 price target on the stock.
  • 9/1/2017 – Thermo Fisher Scientific had its “buy” rating reaffirmed by analysts at Cowen and Company. They now have a $200.00 price target on the stock.
  • 8/22/2017 – Thermo Fisher Scientific had its “buy” rating reaffirmed by analysts at Argus. They noted that the move was a valuation call. They noted that the move was a valuation call.

Thermo Fisher Scientific Inc (NYSE TMO) opened at 190.33 on Wednesday. The company has a market cap of $74.25 billion, a PE ratio of 33.16 and a beta of 1.05. Thermo Fisher Scientific Inc has a 52 week low of $139.07 and a 52 week high of $194.30. The firm’s 50-day moving average is $185.02 and its 200-day moving average is $173.34.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Wednesday, July 26th. The medical research company reported $2.30 EPS for the quarter, beating analysts’ consensus estimates of $2.27 by $0.03. The firm had revenue of $5 billion for the quarter, compared to analyst estimates of $4.92 billion. Thermo Fisher Scientific had a return on equity of 15.97% and a net margin of 11.80%. The company’s revenue for the quarter was up 10.2% on a year-over-year basis. During the same period in the prior year, the firm posted $2.03 EPS. On average, analysts expect that Thermo Fisher Scientific Inc will post $9.35 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Monday, October 16th. Stockholders of record on Friday, September 15th will be issued a dividend of $0.15 per share. This represents a $0.60 dividend on an annualized basis and a dividend yield of 0.32%. The ex-dividend date is Thursday, September 14th. Thermo Fisher Scientific’s dividend payout ratio is currently 10.45%.

In related news, Director Jim P. Manzi sold 11,318 shares of the firm’s stock in a transaction dated Friday, August 18th. The shares were sold at an average price of $172.94, for a total transaction of $1,957,334.92. Following the transaction, the director now directly owns 38,757 shares of the company’s stock, valued at $6,702,635.58. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, SVP Gregory J. Herrema sold 30,000 shares of the firm’s stock in a transaction dated Wednesday, August 2nd. The stock was sold at an average price of $176.02, for a total transaction of $5,280,600.00. Following the transaction, the senior vice president now directly owns 67,016 shares in the company, valued at $11,796,156.32. The disclosure for this sale can be found here. Insiders have sold 52,738 shares of company stock valued at $9,302,112 in the last three months. Insiders own 0.49% of the company’s stock.

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with MarketBeat.com's FREE daily email newsletter.